Centauri Therapeutics
9 articles with Centauri Therapeutics
-
Biopharma and life sciences companies from across the globe provide updates to their pipelines and businesses.
-
Centauri Therapeutics Closes £24 Million GBP Series A Investment Round
2/16/2022
Centauri Therapeutics Limited, an immunotherapy company founded by Animatrix Founders LLP and focused on the treatment of infectious diseases, announced the close of its £24 million GBP Series A investment round.
-
Centauri Therapeutics to Attend Scientific and Investor Conferences
9/30/2019
Centauri Therapeutics, an immunotherapy company active in oncology and infectious diseases, announces that it will attend the following scientific and investor conferences
-
Centauri response by Dr Mike Westby, CEO of Centauri Therapeutics, to Dr Rick Bright, BARDA, Forbes article 10 May 19, “Building New Models To Support The Ailing Antibiotics Market”
5/23/2019
Centauri Therapeutics (“Centauri”) is an immunotherapy company active in oncology and infectious diseases.
-
Centauri's AlphamerTM Platform highlighted at 4th Annual Advances in Immuno-Oncology Congress
5/22/2019
Centauri Therapeutics (“Centauri”), an immunotherapy company active in oncology and infectious diseases, announces that Mel Glossop, Head of Chemistry at Centauri, presented at the 4th Annual Advances in immune-Oncology Congress London, on 20 – 21 May.
-
Centauri Therapeutics to present at 29th European Congress of Clinical Microbiology & Infectious Diseases
4/10/2019
Jennifer Schneider, PhD. Vice President, Business Development at Centauri Therapeutics, will be presenting during the “Therapeutics pipeline corner” session, at 12.15pm CET on 14 April 2019.
-
Centauri Therapeutics Receives Innovate UK Biomedical Catalyst Award
9/11/2017
-
Centauri Therapeutics Closes £2.5 Million Fundraising
2/20/2017
-
Centauri Therapeutics Extends Research Partnership With Peakdale Molecular Ltd.
7/11/2016